Matthew R. Smith, MD, PhD, presents the case of a 82-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.
An 82-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
An expert in prostate cancer discusses the typical follow-up and monitoring approaches for a patient with metastatic CRPC.
Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC).
Prostate cancer expert, Matthew R. Smith, MD, PhD, shares his thoughts about importance of testing in treatment of metastatic castration-resistant prostate cancer (mCRPC).
Dr Matthew Smith discusses next generation androgen receptor inhibitors and data from clinical trials with these agents.
Matthew R. Smith, MD, PhD, shares his personal experience using darolutamide for patients with prostate cancer.
Prostate cancer expert Dr Smith elaborates on treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on systemic therapy.
Matthew R. Smith, MD, PhD, discusses areas of unmet needs and clinical pearls for the management of patients with mCRPC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
